{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T21:19:21Z","timestamp":1717795161881},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,1,21]],"date-time":"2017-01-21T00:00:00Z","timestamp":1484956800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s11523-017-0477-6","type":"journal-article","created":{"date-parts":[[2017,1,21]],"date-time":"2017-01-21T05:10:03Z","timestamp":1484975403000},"page":"229-234","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer"],"prefix":"10.1007","volume":"12","author":[{"given":"Michael","family":"Kosmin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Makris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noorulhuda","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Woolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Miles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anwar R.","family":"Padhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,21]]},"reference":[{"key":"477_CR1","doi-asserted-by":"crossref","unstructured":"Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280\u201390.","DOI":"10.1158\/0008-5472.CAN-08-1776"},{"key":"477_CR2","doi-asserted-by":"crossref","unstructured":"Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R, et al. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther. 2010;9(10):2689\u201399.","DOI":"10.1158\/1535-7163.MCT-10-0644"},{"issue":"2","key":"477_CR3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","volume":"128","author":"TT Junttila","year":"2011","unstructured":"Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128(2):347\u201356.","journal-title":"Breast Cancer Res Treat"},{"key":"477_CR4","doi-asserted-by":"crossref","unstructured":"Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16):2698\u2013704.","DOI":"10.1200\/JCO.2009.26.2071"},{"key":"477_CR5","doi-asserted-by":"crossref","unstructured":"Burris H a., Rugo HS, Vukelja SJ, Vogel CL, Borson R a., Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398\u2013405.","DOI":"10.1200\/JCO.2010.29.5865"},{"key":"477_CR6","doi-asserted-by":"crossref","unstructured":"Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30(26):3234\u201341.","DOI":"10.1200\/JCO.2011.40.5902"},{"key":"477_CR7","doi-asserted-by":"crossref","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","DOI":"10.1056\/NEJMoa1209124"},{"issue":"1","key":"477_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cpdd.9","volume":"2","author":"M Gupta","year":"2013","unstructured":"Gupta M, Wang B, Carrothers TJ, LoRusso PM, Chu YW, Shih T, et al. Effects of trastuzumab emtansine (T-DM1) on Qt interval and safety of pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Pharmacol Drug Dev. 2013;2(1):11\u201324.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"477_CR9","doi-asserted-by":"crossref","unstructured":"Hurvitz SA, Dirix L, Kocsis J, Bianchi G V., Lu J, Vinholes J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013;31(9):1157\u201363.","DOI":"10.1200\/JCO.2012.44.9694"},{"issue":"25","key":"477_CR10","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1200\/JCO.2013.54.4999","volume":"32","author":"V Di\u00e9ras","year":"2014","unstructured":"Di\u00e9ras V, Harbeck N, Budd GT, Greenson JK, Guardino AE, Samant M, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol. 2014;32(25):2750\u20137.","journal-title":"J Clin Oncol"},{"key":"477_CR11","doi-asserted-by":"crossref","unstructured":"Force J, Saxena R, Schneider BP, Storniolo AM, Sledge GW, Chalasani N, et al. Nodular regenerative hyperplasia after treatment with trastuzumab emtansine. J Clin Oncol. 2016;34(3):e9\u201312.","DOI":"10.1200\/JCO.2013.49.8543"},{"key":"477_CR12","unstructured":"Poon KA, Flagella K, Beyer J, Tibbitts J, Kaur S, Saad O, et al. Preclinical safety pro fi le of trastuzumab emtansine ( T-DM1 ): Mechanism of action of its cytotoxic component retained with improved tolerability. Toxicol Appl Pharmacol. The Authors; 2013;273(2):298\u2013313."},{"key":"477_CR13","doi-asserted-by":"crossref","unstructured":"Padhani AR. Diffusion magnetic resonance imaging in cancer patient management. Semin Radiat Oncol. 2011;21(2):119\u201340.","DOI":"10.1016\/j.semradonc.2010.10.004"},{"issue":"5","key":"477_CR14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/jmri.24548","volume":"39","author":"AR Padhani","year":"2014","unstructured":"Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, De Bono JS. Therapy monitoring of skeletal metastases with whole-body diffusion MRI. J Magn Reson Imaging. 2014;39(5):1049\u201378.","journal-title":"J Magn Reson Imaging"},{"key":"477_CR15","doi-asserted-by":"crossref","unstructured":"Woolf DK, Padhani a. R, Makris a. Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care? Ann Oncol. 2015;26(6):1048\u201357.","DOI":"10.1093\/annonc\/mdu558"},{"issue":"1","key":"477_CR16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2214\/AJR.11.8185","volume":"200","author":"AR Padhani","year":"2013","unstructured":"Padhani AR, Van Ree K, Collins DJ, D\u2019Sa S, Makris A. Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI. Am J Roentgenol. 2013;200(1):163\u201370.","journal-title":"Am J Roentgenol"},{"issue":"4","key":"477_CR17","first-page":"266","volume":"12","author":"L Mandal","year":"2011","unstructured":"Mandal L, Mandal SK, Bandyopadhyay D, Datta S. Correlation of portal vein diameter and splenic size with gastro-oesophageal varices in cirrhosis of liver. J Indian Acad Clin Med. 2011;12(4):266\u201370.","journal-title":"J Indian Acad Clin Med"},{"key":"477_CR18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/j.1600-0455.2003.00123.x","volume":"44","author":"I Ciray","year":"2003","unstructured":"Ciray I, Lindman H, Astrom G, Wanders A, Bergh J, Ahlstrom H. Effect of Granulocyte Colony-Stimulating Factor (G-CSF)-supported chemotherapy on MR imaging of normal red bone marrow in breast cancer patients with focal bone metastases. Acta Radiol. 2003;44:472\u201384.","journal-title":"Acta Radiol"},{"issue":"7","key":"477_CR19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2174\/138920012802138598","volume":"13","author":"B-Q Shen","year":"2012","unstructured":"Shen B-Q, Bumbaca D, Saad O, Yue Q, Pastuskovas C, Khojasteh SC, et al. Catabolic fate and pharmacokinetic characterization of T-DM1. Curr Drug Metab. 2012;13(7):901\u201310.","journal-title":"Curr Drug Metab"},{"key":"477_CR20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1102\/1470-7330.2011.9001","volume":"11","author":"AR Padhani","year":"2011","unstructured":"Padhani AR, Gogbashian A. Bony metastases: assessing response to therapy with whole-body diffusion MRI. Cancer Imaging. 2011;11:S1\u2013S17.","journal-title":"Cancer Imaging"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-017-0477-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11523-017-0477-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-017-0477-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T04:47:35Z","timestamp":1498366055000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11523-017-0477-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,21]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["477"],"URL":"https:\/\/doi.org\/10.1007\/s11523-017-0477-6","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,21]]}}}